JP2016531144A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016531144A5 JP2016531144A5 JP2016541921A JP2016541921A JP2016531144A5 JP 2016531144 A5 JP2016531144 A5 JP 2016531144A5 JP 2016541921 A JP2016541921 A JP 2016541921A JP 2016541921 A JP2016541921 A JP 2016541921A JP 2016531144 A5 JP2016531144 A5 JP 2016531144A5
- Authority
- JP
- Japan
- Prior art keywords
- fxr
- interferon alpha
- agonist
- subject
- farnesoid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 9
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 claims 5
- 241000700721 Hepatitis B virus Species 0.000 claims 4
- 108010050904 Interferons Proteins 0.000 claims 4
- 102000014150 Interferons Human genes 0.000 claims 4
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 4
- QDGZDCVAUDNJFG-FXQIFTODSA-N entecavir (anhydrous) Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)C1=C QDGZDCVAUDNJFG-FXQIFTODSA-N 0.000 claims 4
- 229940079322 interferon Drugs 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 3
- 102100038495 Bile acid receptor Human genes 0.000 claims 2
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims 2
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 2
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 2
- 229960001997 adefovir Drugs 0.000 claims 2
- 229940002637 baraclude Drugs 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229960000980 entecavir Drugs 0.000 claims 2
- 229940097709 hepsera Drugs 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 2
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 claims 2
- 229960001601 obeticholic acid Drugs 0.000 claims 2
- 229940002988 pegasys Drugs 0.000 claims 2
- 108010092853 peginterferon alfa-2a Proteins 0.000 claims 2
- 108010092851 peginterferon alfa-2b Proteins 0.000 claims 2
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 claims 2
- SGOIRFVFHAKUTI-ZCFIWIBFSA-N tenofovir (anhydrous) Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 claims 2
- 229940063032 tyzeka Drugs 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306245 | 2013-09-11 | ||
| EP13306245.5 | 2013-09-11 | ||
| PCT/EP2014/069312 WO2015036442A1 (en) | 2013-09-11 | 2014-09-10 | Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018126614A Division JP6402277B1 (ja) | 2013-09-11 | 2018-07-03 | Ｂ型肝炎ウイルス感染症を処置するための方法及び医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016531144A JP2016531144A (ja) | 2016-10-06 |
| JP2016531144A5 true JP2016531144A5 (enExample) | 2018-04-05 |
| JP6366721B2 JP6366721B2 (ja) | 2018-08-01 |
Family
ID=49231404
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016541921A Active JP6366721B2 (ja) | 2013-09-11 | 2014-09-10 | Ｂ型肝炎ウイルス感染症を処置するための方法及び医薬組成物 |
| JP2018126614A Active JP6402277B1 (ja) | 2013-09-11 | 2018-07-03 | Ｂ型肝炎ウイルス感染症を処置するための方法及び医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018126614A Active JP6402277B1 (ja) | 2013-09-11 | 2018-07-03 | Ｂ型肝炎ウイルス感染症を処置するための方法及び医薬組成物 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9895380B2 (enExample) |
| EP (2) | EP3711762A1 (enExample) |
| JP (2) | JP6366721B2 (enExample) |
| KR (1) | KR101949251B1 (enExample) |
| CN (2) | CN105764569B (enExample) |
| AU (2) | AU2014320463B2 (enExample) |
| BR (1) | BR112016005507B1 (enExample) |
| CA (1) | CA2923090C (enExample) |
| CY (1) | CY1123962T1 (enExample) |
| DK (1) | DK3043865T3 (enExample) |
| EA (1) | EA031003B1 (enExample) |
| ES (1) | ES2846183T3 (enExample) |
| HR (1) | HRP20201953T1 (enExample) |
| HU (1) | HUE052856T2 (enExample) |
| IL (1) | IL244431B (enExample) |
| LT (1) | LT3043865T (enExample) |
| MX (1) | MX377523B (enExample) |
| MY (1) | MY186752A (enExample) |
| PH (1) | PH12016500431A1 (enExample) |
| PL (1) | PL3043865T3 (enExample) |
| PT (1) | PT3043865T (enExample) |
| RS (1) | RS61540B1 (enExample) |
| SI (1) | SI3043865T1 (enExample) |
| SM (1) | SMT202000669T1 (enExample) |
| WO (1) | WO2015036442A1 (enExample) |
Families Citing this family (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA34470B1 (fr) | 2010-07-22 | 2013-08-01 | Gilead Sciences Inc | Procédés et composés pour traiter des infections à virus paramyxoviridae |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| CN115990171A (zh) * | 2014-09-28 | 2023-04-21 | 华辉安健（北京）生物科技有限公司 | 聚合胆汁酸衍生物抑制乙型肝炎病毒和丁型肝炎病毒和ntcp运输 |
| TWI767201B (zh) | 2014-10-29 | 2022-06-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| NZ735126A (en) | 2015-03-31 | 2022-10-28 | Enanta Pharm Inc | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| PE20180690A1 (es) | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
| MX394858B (es) | 2015-09-16 | 2025-03-24 | Gilead Sciences Inc | Compuestos de formula i para usarse en el tratamiento de infecciones por virus arenaviridae y coronaviridae |
| WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017189651A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017189652A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017201150A1 (en) * | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| WO2017201152A1 (en) * | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017201155A1 (en) * | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
| CA3026512A1 (en) | 2016-06-13 | 2017-12-21 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| PT3507276T (pt) | 2016-09-02 | 2022-01-11 | Gilead Sciences Inc | Compostos moduladores do recetor de tipo toll |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| EP3518918A4 (en) * | 2016-09-28 | 2020-04-22 | Eiger Biopharmaceuticals, Inc. | METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS |
| JP2019537557A (ja) | 2016-10-04 | 2019-12-26 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｆｘｒアゴニストとしてのイソキサゾール類似体およびその使用方法 |
| MA46535A (fr) | 2016-10-14 | 2019-08-21 | Prec Biosciences Inc | Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b |
| US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
| CN108017636A (zh) * | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
| TWI714820B (zh) | 2017-01-31 | 2021-01-01 | 美商基利科學股份有限公司 | 替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型 |
| CA3056072C (en) | 2017-03-14 | 2022-08-23 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
| EP4122464B1 (en) | 2017-03-28 | 2024-05-15 | Gilead Sciences, Inc. | Therapeutic combinations for treating liver diseases |
| US20210085662A1 (en) * | 2017-03-30 | 2021-03-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| KR20190141747A (ko) | 2017-05-01 | 2019-12-24 | 길리애드 사이언시즈, 인코포레이티드 | (S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태 |
| EP4512475A3 (en) | 2017-07-11 | 2025-05-14 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| KR102114394B1 (ko) | 2017-08-30 | 2020-05-22 | 경희대학교 산학협력단 | 벤조페논 유도체, 이의 제조방법 및 이를 포함하는 b형간염 치료용 약학적 조성물 |
| US10689391B2 (en) | 2017-12-12 | 2020-06-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| SI3752501T1 (sl) | 2018-02-13 | 2023-08-31 | Gilead Sciences, Inc. | Inhibitorji pd-1/pd-l1 |
| WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| CA3093130C (en) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| SI3820572T1 (sl) | 2018-07-13 | 2023-12-29 | Gilead Sciences, Inc. | Inhibitorji pd-1/pd-l1 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| JP7158577B2 (ja) | 2018-10-24 | 2022-10-21 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| CA3117556A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| TWI721624B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| LT3911647T (lt) | 2019-01-15 | 2024-03-25 | Gilead Sciences, Inc. | Izoksazolo junginys kaip fxr agonistas ir jį apimančios farmacinės kompozicijos |
| CA3129949C (en) | 2019-02-19 | 2024-04-30 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| JP7350871B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | ２’３’－環状ジヌクレオチドおよびそのプロドラッグ |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TW202104210A (zh) | 2019-04-17 | 2021-02-01 | 美商基利科學股份有限公司 | Hiv蛋白酶抑制劑 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US11555032B2 (en) | 2019-05-13 | 2023-01-17 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| CN114245807B (zh) | 2019-06-25 | 2025-05-02 | 吉利德科学公司 | Flt3l-fc融合蛋白和使用方法 |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| KR20220035366A (ko) * | 2019-07-18 | 2022-03-22 | 엔요 파마 | Eyp001을 사용하는 개선된 치료 |
| MX2021016022A (es) * | 2019-07-18 | 2022-02-03 | Enyo Pharma | Efecto sinergico de eyp001 e ifn para el tratamiento de la infeccion por hbv. |
| US20220241376A1 (en) * | 2019-07-18 | 2022-08-04 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| MY208114A (en) | 2019-09-30 | 2025-04-16 | Gilead Sciences Inc | Hbv vaccines and methods treating hbv |
| WO2021108974A1 (en) * | 2019-12-03 | 2021-06-10 | Gannex Pharma Co., Ltd | Compounds for modulating activity of fxr and uses thereof |
| CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
| MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| EP4090327B1 (en) * | 2020-01-15 | 2025-03-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fxr agonists for treating an infection by hepatitis d virus |
| AU2021214911A1 (en) | 2020-01-27 | 2022-07-21 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
| KR20220153619A (ko) | 2020-03-12 | 2022-11-18 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 뉴클레오사이드의 제조 방법 |
| EP4121012A1 (en) * | 2020-03-18 | 2023-01-25 | Metacrine, Inc. | Formulations of a farnesoid x receptor agonist |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| KR20200049728A (ko) | 2020-04-24 | 2020-05-08 | 경희대학교 산학협력단 | 벤조페논 유도체, 이의 제조방법 및 이를 포함하는 b형간염 치료용 약학적 조성물 |
| JP7664287B2 (ja) | 2020-05-29 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | レムデシビル治療方法 |
| AU2021296841B2 (en) | 2020-06-24 | 2025-01-23 | Gilead Sciences, Inc. | 1'-cyano nucleoside analogs and uses thereof |
| BR112023002164A2 (pt) | 2020-08-07 | 2023-03-14 | Gilead Sciences Inc | Profármacos de análogos de nucleotídeos de fosfonamida e seu uso farmacêutico |
| JP7559223B2 (ja) | 2020-08-24 | 2024-10-01 | ギリアード サイエンシーズ， インコーポレイテッド | リン脂質化合物及びその使用 |
| KR20250111239A (ko) | 2020-08-27 | 2025-07-22 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스 감염 치료를 위한 화합물 및 방법 |
| WO2022076683A1 (en) * | 2020-10-07 | 2022-04-14 | Intercept Pharmaceuticals, Inc. | Methods of treating coronaviral infection with obeticholic acid |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| JP2024502673A (ja) | 2021-01-14 | 2024-01-22 | ウエヌイグレックオ・ファーマ | Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果 |
| EP4324825A4 (en) * | 2021-04-16 | 2025-08-27 | Beijing Best Pathway Man Consulting Center Limited Partnership | FXR REGULATOR, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION THEREOF AND ITS USE |
| TW202348237A (zh) | 2021-05-13 | 2023-12-16 | 美商基利科學股份有限公司 | TLR8調節化合物及抗HBV siRNA療法之組合 |
| EP4346772A1 (en) | 2021-05-26 | 2024-04-10 | Gilead Sciences, Inc. | Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs |
| EP4359389A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US12116380B2 (en) | 2021-08-18 | 2024-10-15 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| JP2025014084A (ja) * | 2021-12-07 | 2025-01-29 | 慶應義塾 | ウイルス増殖抑制剤 |
| CA3244278A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences Inc | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| KR20240154646A (ko) | 2022-03-02 | 2024-10-25 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스성 감염 치료를 위한 화합물 및 방법 |
| MX2024010671A (es) | 2022-03-03 | 2024-09-11 | Gilead Sciences Inc | Compuestos antivirales y metodos de elaboracion y uso de los mismos. |
| WO2023168254A1 (en) | 2022-03-03 | 2023-09-07 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| WO2023195798A1 (ko) * | 2022-04-06 | 2023-10-12 | (주)샤페론 | 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 폐섬유증 예방 또는 치료용 조성물 |
| EP4536223A1 (en) | 2022-06-06 | 2025-04-16 | Gilead Sciences, Inc. | Methods for treatment of viral infections including sars-cov-2 |
| WO2024006376A1 (en) | 2022-06-29 | 2024-01-04 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| US20240043466A1 (en) | 2022-06-30 | 2024-02-08 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| US20240309028A1 (en) | 2023-02-16 | 2024-09-19 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| WO2025049699A1 (en) | 2023-08-31 | 2025-03-06 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| WO2025049493A1 (en) | 2023-08-31 | 2025-03-06 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| WO2025054278A1 (en) | 2023-09-06 | 2025-03-13 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| TW202517647A (zh) | 2023-09-28 | 2025-05-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994022896A1 (fr) * | 1993-03-31 | 1994-10-13 | Tokyo Tanabe Company Limited | Ameliorant de la cholestase |
| US6005086A (en) | 1995-01-13 | 1999-12-21 | The Salk Institute For Biological Studies | Farnesoid activated receptor polypeptides, and nucleic acid encoding the same |
| JP2002532729A (ja) | 1998-12-23 | 2002-10-02 | グラクソ グループ リミテッド | 核内受容体のリガンドのアッセイ |
| WO2000040965A1 (en) | 1999-01-07 | 2000-07-13 | Tularik, Inc. | Fxr receptor-mediated modulation of cholesterol metabolism |
| US20020132223A1 (en) | 1999-03-26 | 2002-09-19 | City Of Hope | Methods for modulating activity of the FXR nuclear receptor |
| EP1185277B1 (en) | 1999-06-11 | 2005-10-26 | Allergan, Inc. | Use of FXR synthetic ligands for the treatment of diseseas linked to cholesterol imbalance and colon cancer |
| ES2215719T3 (es) | 1999-09-08 | 2004-10-16 | Glaxo Group Limited | Antagonista ppar oxazol. |
| EP1392714B1 (en) | 2001-03-12 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for fxr |
| EP1285914B1 (en) | 2001-08-13 | 2007-12-19 | PheneX Pharmaceuticals AG | Nr1h4 nuclear receptor binding compounds |
| WO2003016280A1 (en) | 2001-08-13 | 2003-02-27 | Lion Bioscience Ag | Nr1h4 nuclear receptor binding compounds |
| US6696473B2 (en) | 2001-12-21 | 2004-02-24 | X-Ceptor Therapeutics, Inc. | Heterocyclic modulators of nuclear receptors |
| US20050107475A1 (en) | 2002-03-21 | 2005-05-19 | Jones Stacey A. | Methods of using farnesoid x receptor (frx) agonists |
| US6987121B2 (en) | 2002-04-25 | 2006-01-17 | Smithkline Beecham Corporation | Compositions and methods for hepatoprotection and treatment of cholestasis |
| ITMI20021532A1 (it) | 2002-07-12 | 2004-01-12 | Roberto Pellicciari | Composti chimici |
| AU2003290796A1 (en) | 2002-11-14 | 2004-06-15 | The Scripps Research Institute | Non-steroidal fxr agonists |
| US20050143449A1 (en) | 2002-11-15 | 2005-06-30 | The Salk Institute For Biological Studies | Non-steroidal farnesoid X receptor modulators and methods for the use thereof |
| AU2003290700A1 (en) | 2002-11-22 | 2004-06-18 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
| KR100545898B1 (ko) | 2003-07-02 | 2006-01-25 | 동부아남반도체 주식회사 | 반도체 소자의 양자점 형성방법 |
| WO2005032549A1 (en) | 2003-09-26 | 2005-04-14 | Smithkline Beecham Corporation | Compositions and methods for treatment of fibrosis |
| EP1568706A1 (en) | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| ES2533993T3 (es) * | 2004-03-12 | 2015-04-16 | Intercept Pharmaceuticals, Inc. | Tratamiento de fibrosis usando ligandos de FXR |
| JP2005281155A (ja) | 2004-03-29 | 2005-10-13 | Japan Health Science Foundation | Ｆｘｒ活性化を介したコレステロールホメオスタシス関連遺伝子転写活性調節剤 |
| WO2005092328A1 (ja) | 2004-03-29 | 2005-10-06 | Japan Health Sciences Foundation | Ｆｘｒ活性化化合物 |
| JP4825977B2 (ja) | 2004-04-02 | 2011-11-30 | 財団法人ヒューマンサイエンス振興財団 | Ｆｘｒ活性化を介したコレステロールホメオスタシス関連遺伝子転写活性調節剤 |
| EP1776112A4 (en) | 2004-08-10 | 2009-11-25 | Exelixis Inc | HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL AGENTS |
| US20060252670A1 (en) * | 2004-10-14 | 2006-11-09 | Intercept Pharmaceuticals Inc. | Method of reducing drug-induced adverse side effects in a patient |
| WO2007052843A1 (ja) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
| ATE526318T1 (de) | 2005-12-19 | 2011-10-15 | Glaxosmithkline Llc | Farnesoid-x-rezeptor-agonisten |
| EP1984360B1 (en) | 2006-02-03 | 2014-01-15 | Eli Lilly & Company | Compounds and methods for modulating FX-receptors |
| PL2029547T3 (pl) | 2006-05-24 | 2010-09-30 | Lilly Co Eli | Agoniści FXR |
| ATE460403T1 (de) | 2006-05-24 | 2010-03-15 | Lilly Co Eli | Verbindungen und verfahren zur modulierung von fx-rezeptoren |
| SI2040713T1 (sl) | 2006-06-27 | 2014-11-28 | Intercept Pharmaceuticals, Inc. | Derivati žolčne kisline kot FXR ligandi za preprečevanje ali zdravljenje bolezni ali stanj, posredovanih s FXR |
| MX2008015923A (es) | 2006-06-29 | 2009-01-13 | Hoffmann La Roche | Derivados de bencimidazol, metodo para su produccion, su uso como agonistas fxr y preparaciones farmaceuticas que los contienen. |
| US20080038435A1 (en) | 2006-08-01 | 2008-02-14 | Van Miller | Precursor Formulation for Whippable Topping or Dessert Filling |
| EP1886685A1 (en) * | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
| EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
| CL2007003035A1 (es) | 2006-10-24 | 2008-05-16 | Smithkline Beechman Corp | Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos, |
| CN101679297B (zh) | 2006-12-08 | 2012-01-11 | 埃克塞利希斯股份有限公司 | Lxr和fxr调节剂 |
| US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| US20080300235A1 (en) | 2007-06-01 | 2008-12-04 | Wyeth | FXR Agonists for Reducing LOX-1 Expression |
| BRPI0812521A2 (pt) * | 2007-06-13 | 2015-06-23 | Glaxosmithkline Llc | Composto, composição farmacêutica, método para o tratamento de doença em um mamífero, processo para a preparação de um composto, e, uso de um composto |
| US20110034507A1 (en) | 2007-07-02 | 2011-02-10 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| ES2387230T3 (es) | 2007-08-27 | 2012-09-18 | F. Hoffmann-La Roche Ag | Derivados de bencimidazol utilizados como agonistas del FXR |
| US8338628B2 (en) | 2007-08-28 | 2012-12-25 | City Of Hope | Method of synthesizing alkylated bile acid derivatives |
| WO2009062874A2 (en) | 2007-11-15 | 2009-05-22 | F. Hoffmann-La Roche Ag | Benzimidazole derivatives and their use as fxr agonists |
| US20090215748A1 (en) | 2007-12-20 | 2009-08-27 | Wyeth | FXR agonists for treating vitamin D associated diseases |
| US7816540B2 (en) | 2007-12-21 | 2010-10-19 | Hoffmann-La Roche Inc. | Carboxyl- or hydroxyl-substituted benzimidazole derivatives |
| EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
| EP2128158A1 (en) | 2008-05-26 | 2009-12-02 | Phenex Pharmaceuticals AG | Heterocyclic cyclopropyl-substituted FXR binding compounds |
| ES2407180T3 (es) | 2008-09-11 | 2013-06-12 | F. Hoffmann-La Roche Ag | Nuevos derivados de bencimidazol |
| CN102164899B (zh) | 2008-09-25 | 2014-11-26 | 霍夫曼-拉罗奇有限公司 | 用作抗异常脂肪血症及相关疾病的fxr调节剂的取代的吲唑或四氢吲唑类 |
| MX2011002793A (es) | 2008-09-25 | 2011-04-05 | Hoffmann La Roche | Derivados de 3-amino-indazol o de 3-amino-4,5,6,7-tetrahidro-indaz ol. |
| JP2012505849A (ja) | 2008-10-15 | 2012-03-08 | エフ．ホフマン−ラ ロシュ アーゲー | 新規なベンズイミダゾール誘導体 |
| WO2010069604A1 (en) | 2008-12-19 | 2010-06-24 | Royal College Of Surgeons In Ireland | Treatment of diarrhoea |
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| US8309581B2 (en) | 2009-09-29 | 2012-11-13 | Hoffmann-La Roche Inc. | Benzimidazole derivatives |
| DE102010012226A1 (de) * | 2010-03-19 | 2011-09-22 | Acrovis Biostructures Gmbh | Pharmazeutisches Kombinationspräparat |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| US9930947B2 (en) | 2015-09-19 | 2018-04-03 | Hot Concepts, LLC | Payment card enclosure system and methods of manufacturing and use |
-
2014
- 2014-09-10 ES ES14771231T patent/ES2846183T3/es active Active
- 2014-09-10 SM SM20200669T patent/SMT202000669T1/it unknown
- 2014-09-10 EA EA201690556A patent/EA031003B1/ru unknown
- 2014-09-10 BR BR112016005507-1A patent/BR112016005507B1/pt active IP Right Grant
- 2014-09-10 KR KR1020167009528A patent/KR101949251B1/ko active Active
- 2014-09-10 MY MYPI2016000447A patent/MY186752A/en unknown
- 2014-09-10 HU HUE14771231A patent/HUE052856T2/hu unknown
- 2014-09-10 US US14/917,958 patent/US9895380B2/en active Active
- 2014-09-10 RS RS20201465A patent/RS61540B1/sr unknown
- 2014-09-10 SI SI201431731T patent/SI3043865T1/sl unknown
- 2014-09-10 DK DK14771231.9T patent/DK3043865T3/da active
- 2014-09-10 EP EP20173231.0A patent/EP3711762A1/en not_active Withdrawn
- 2014-09-10 EP EP14771231.9A patent/EP3043865B1/en active Active
- 2014-09-10 WO PCT/EP2014/069312 patent/WO2015036442A1/en not_active Ceased
- 2014-09-10 CN CN201480059747.2A patent/CN105764569B/zh active Active
- 2014-09-10 PL PL14771231T patent/PL3043865T3/pl unknown
- 2014-09-10 CA CA2923090A patent/CA2923090C/en active Active
- 2014-09-10 HR HRP20201953TT patent/HRP20201953T1/hr unknown
- 2014-09-10 CN CN201910760011.2A patent/CN110404073B/zh active Active
- 2014-09-10 AU AU2014320463A patent/AU2014320463B2/en active Active
- 2014-09-10 PT PT147712319T patent/PT3043865T/pt unknown
- 2014-09-10 LT LTEP14771231.9T patent/LT3043865T/lt unknown
- 2014-09-10 MX MX2016003216A patent/MX377523B/es active IP Right Grant
- 2014-09-10 JP JP2016541921A patent/JP6366721B2/ja active Active
-
2016
- 2016-03-03 IL IL244431A patent/IL244431B/en active IP Right Grant
- 2016-03-07 PH PH12016500431A patent/PH12016500431A1/en unknown
-
2018
- 2018-02-19 US US15/898,944 patent/US10071108B2/en active Active
- 2018-07-03 JP JP2018126614A patent/JP6402277B1/ja active Active
- 2018-09-28 AU AU2018236856A patent/AU2018236856B2/en active Active
-
2020
- 2020-12-08 CY CY20201101163T patent/CY1123962T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016531144A5 (enExample) | ||
| HRP20201953T1 (hr) | Postupci i farmaceutski pripravci za liječenje virusne infekcije hepatitisom b | |
| JP2013522302A5 (enExample) | ||
| JP2019068829A5 (enExample) | ||
| JP2015517489A5 (enExample) | ||
| JP2016508134A5 (enExample) | ||
| JP2010503396A5 (enExample) | ||
| JP2017524682A5 (enExample) | ||
| JP2017504626A5 (enExample) | ||
| JP2017203033A5 (enExample) | ||
| JP2017186358A5 (enExample) | ||
| JP2016513703A5 (enExample) | ||
| RU2016138735A (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| JP2015038149A5 (enExample) | ||
| JP2012136541A5 (enExample) | ||
| NZ743463A (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b | |
| JP2013241424A5 (enExample) | ||
| JP2019511542A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| EP3370759A1 (en) | Combination therapy of an hbv capsid assembly inhibitor and an interferon | |
| AR062453A1 (es) | Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia | |
| JP2017537084A5 (enExample) | ||
| JOP20210249A1 (ar) | مشتقات البيرميدون الحلقية المدمجة للاستخدام في علاج عدوىhbv أو الأمراض التي يسببها فيروس hbv | |
| JP2016539125A5 (enExample) | ||
| MX2016012799A (es) | Metodos para tratar el virus de la hepatitis c. |